Sophia Randolph
Chief Tech/Sci/R&D Officer chez ALX ONCOLOGY HOLDINGS INC.
Fortune : 4 M $ au 31/03/2024
Profil
Sophia Randolph is currently the Director & Chief Medical Officer at ALX Oncology Holdings, Inc. She previously worked as the Director-Clinical Sciences & Oncology at Merck & Co., Inc. from 2007 to 2008 and as the Executive Director-Oncology at Pfizer Inc. from 2015 to 2016.
Dr. Randolph completed her undergraduate degree at Harvard University and obtained a doctorate from the University of Michigan.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
14/02/2024 | 342 349 ( 0,68% ) | 4 M $ | 31/03/2024 |
Postes actifs de Sophia Randolph
Sociétés | Poste | Début |
---|---|---|
ALX ONCOLOGY HOLDINGS INC. | Chief Tech/Sci/R&D Officer | 01/06/2016 |
Anciens postes connus de Sophia Randolph
Sociétés | Poste | Fin |
---|---|---|
PFIZER, INC. | Corporate Officer/Principal | 01/04/2016 |
MERCK & CO., INC. | Corporate Officer/Principal | 01/05/2008 |
Formation de Sophia Randolph
Harvard University | Undergraduate Degree |
University of Michigan | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
MERCK & CO., INC. | Health Technology |
PFIZER, INC. | Health Technology |
ALX ONCOLOGY HOLDINGS INC. | Health Technology |